2026
Prof Wang was invited to attend Tigermed’s ASCO Pre-Event Webinar as a Speaker to introduce Qurgen’s breakthrough cell converting cancer
Our Key Innovations
- Qurgen has developed several breakthrough transcription factor (TF) protein drugs
- Qurgen has developed the 2nd generation of safe protein-induced in vivo disease tissue reprogramming technology
Key Innovations
Rencent news
Apr. 2026
no infusion related reaction (IRR) has occurred during the 48-hour continuous infusion by pump, this indicates a significantly enhanced safety
Mar. 2026
Qurgen has completed SON-DP treatment for multiple late-stage solid tumor patients for over 18-months at low dose levels (2-4.5 mg/kg)
Mar. 2026
Qurgen expanded 4 additional hospitals (Sarah Cannon Research Institute Tennessee, HCA HealthONE Denver, California Research Institute, LLC, Allison, Curtis, Kingsley,
technology platforms
QQ－Protein Delivery Technology Platform
QQ-reagent is a polymer-based protein delivery vehicle that non-covalently associates to protein surfaces and facilitate their entry into cells. This unique delivery system, known as QQ-protein delivery technology...
QQ-Protein Induced Pluripotent Stem Cell Technology Platform
QQ-protein induced pluripotent stem cell (piPSC) technology platform is a new way of converting human somatic cells or human disease cells including cancer cells into piPSCs with remarkable greater than 90% piPSC conversion efficiency...
Protein Induced In Vivo Tissue Reprogramming Technology Platform
QQ-Proteins induced in situ disease tissue reprogramming technology is a cutting-edge approach that allows for the safe and efficient reprogramming of disease or injured or degenerated cells into different types of stem cells in vivo within ...
Clinical Pipeline
Qurgen is investing in scientific and technical excellence for developing and introducing a clinical pipeline of innovative medicines that combat cancer, heart failure, diabetes, eye disease and anti-aging.
On December 7, 2022, the FDA granted a first-in-human Phase I clinical trial IND approval for our leading anti-cancer transcription factor protein drug, “SON-DP” to treat late-stage solid tumors with the focus on breast cancers, ovarian cancer, pancreatic cancer and colorectal cancers (IND Number: 152226, ClinicalTrials.gov ID: NCT05989724). We have engaged with the following 5 hospitals at the Phase Ia dose escalation stage:
- MD Anderson Cancer Center
- Henry Ford Health System
- Carolina BioOncology Institute (CBI)
- Banner MD Anderson at Banner Gateway Medical Center
- Stephenson Cancer Center, University of Oklahoma
Qurgen has also obtained IRB approvals for this Phase I clinical trial of SON-DP. The first patient had undergone treatment in September of 2023. Upon to August of 2024, our clinical data demonstrated the safety of SON-DP drug and displayed initial efficacy of tumor shrinkage and disappearance of smaller metastatic lessons of late-stage solid tumor patients at the mid-dose levels of SON-DP drug.
Applications
These core technologies provide brand-new therapeutic program in treating cancer, heart disease, ophthalmology and other serious diseases, and have wide application prospect in biomedical field.
- Cancer Treatment
- Cardiac Disease
- Anti-aging and Longevity
- Other Serious Diseases
About Qurgen
Qurgen is a clinical stage biotechnology company located in Michigan that was established in 2012. Its founders developed innovative technology platforms that serve as the basis of the company’s operations.